CA
NMRA icon

Clearstead Advisors’s Neumora Therapeutics NMRA Stock Holding History

Clearstead Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Buy
+8,496
New +$16.2K ﹤0.01% 1882

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clearstead Advisors's NMRA Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Neumora Therapeutics (NMRA) in Q2 2026: 8,496 shares worth $14.4K. The stake represents ﹤0.01% of the portfolio and ranks #1882 among its holdings.

113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Clearstead Advisors held 8,496 shares of Neumora Therapeutics worth $14.4K as of Q2 2026.
  • Neumora Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Neumora Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1882 holding.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.